- Invivyd Elects Two New Independent Members to its Board of Directors
- Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
- Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
- Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
- Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
- Invivyd Announces CEO Transition
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
- Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
More ▼
Key statistics
As of last trade, Invivyd Inc (IVVD:NMQ) traded at 1.98, 102.00% above the 52 week low of 0.9802 set on Jun 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.00 |
---|---|
High | 2.03 |
Low | 1.96 |
Bid | 1.98 |
Offer | 1.99 |
Previous close | 2.01 |
Average volume | 434.36k |
---|---|
Shares outstanding | 119.32m |
Free float | 97.61m |
P/E (TTM) | -- |
Market cap | 239.82m USD |
EPS (TTM) | -1.86 USD |
Data delayed at least 15 minutes, as of May 24 2024 19:43 BST.
More ▼